CYTK4:00 PMCytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Updatecytokinetics.com
CYTK6:20 AMCytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Walescytokinetics.com
CYTK4:00 PMCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)cytokinetics.com
CYTK7:30 AMCytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026cytokinetics.com
CYTK4:00 PMCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)cytokinetics.com
CYTK7:30 AMCytokinetics Announces Call for Proposals for Annual Corporate Giving Programcytokinetics.com
CYTK7:30 AMCytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germanycytokinetics.com